ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO091

PPARα in Proximal Tubules Attenuates Ischemic AKI

Session Information

  • AKI: Mechanisms - III
    November 05, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: Acute Kidney Injury

  • 103 AKI: Mechanisms


  • Nimura, Takayuki, Shinshu Daigaku Igakubu Fuzoku Byoin, Matsumoto, Nagano, Japan
  • Aomura, Daiki, Shinshu Daigaku Igakubu Fuzoku Byoin, Matsumoto, Nagano, Japan
  • Yamada, Yosuke, Shinshu Daigaku Igakubu Fuzoku Byoin, Matsumoto, Nagano, Japan
  • Harada, Makoto, Shinshu Daigaku Igakubu Fuzoku Byoin, Matsumoto, Nagano, Japan
  • Hashimoto, Koji, Shinshu Daigaku Igakubu Fuzoku Byoin, Matsumoto, Nagano, Japan
  • Yanagita, Motoko, Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Kamijo, Yuji, Shinshu Daigaku Igakubu Fuzoku Byoin, Matsumoto, Nagano, Japan

Peroxisome proliferator-activated receptor alpha (PPARα) is a nuclear receptor. The renal expression of PPARα is mainly localized in the proximal tubules (PTs). PPARα maintains tissue energy metabolism by regulating fatty acid oxidation (FAO), with several studies reporting a possible renoprotective effect of systemic PPARα against ischemic kidney injury. Since the contribution of renal PPARα to this function is unknown, we addressed the above notion using PT-specific PPARα knock-out mice.


Mice harboring Ndrg1-CreERT2 transgenes were crossed with Ppara flox/flox mice to generate Ndrg1-CreERT2-Ppara flox/flox (PTs-PPARα-CKO) mice, which were intraperitoneally injected with tamoxifen for 3 days to knock out PT PPARα. Then, bilateral 40-minute ischemia-reperfusion (I/R) was conducted on tamoxifen-treated 13-week-old Ppara flox/flox mice (controls) and PTs-PPARα-CKO mice to produce an ischemic acute kidney injury model (n=9 in both groups). A sham operation was also performed (n=3 in each group). All mice were sacrificed 24 hours after I/R or the sham operation.


A deficiency in renal PPARα expression was confirmed in the PTs-PPARα-CKO mice for both I/R and sham procedures. PTs-PPARα-CKO animals subjected to I/R showed significantly higher serum creatinine levels, with pathological findings of more severe renal tubular injury than in controls. Renal cytokine expressions were also significantly higher for PTs-PPARα-CKO with I/R. Although the renal expressions of FAO-related genes were decreased by I/R in both mice groups, those depletions were significantly more severe in the PTs-PPARα-CKO mice. The renal expressions of anti-oxidative stress enzymes were also significantly lower in the PTs-PPARα-CKO mice with I/R versus controls.


PPARα in PTs attenuates ischemic acute kidney injury, presumably through the maintenance of renal FAO and anti-oxidative enzyme expression.